Publication

The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood

Kent, S., Becker, F., Feenstra, T., Tran-Duy, A., Schlackow, I., Tew, M., Zhang, P., Ye, W., Lizheng, S., Herman, W., McEwan, P., Schramm, W., Gray, A., Leal, J., Lamotte, M., Willis, M., Palmer, A. J. & Clarke, P., Nov-2019, In : Pharmacoeconomics. 37, 11, p. 1305-1312 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Kent, S., Becker, F., Feenstra, T., Tran-Duy, A., Schlackow, I., Tew, M., Zhang, P., Ye, W., Lizheng, S., Herman, W., McEwan, P., Schramm, W., Gray, A., Leal, J., Lamotte, M., Willis, M., Palmer, A. J., & Clarke, P. (2019). The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics, 37(11), 1305-1312. https://doi.org/10.1007/s40273-019-00825-1

Author

Kent, Seamus ; Becker, Frauke ; Feenstra, Talitha ; Tran-Duy, An ; Schlackow, Iryna ; Tew, Michelle ; Zhang, Ping ; Ye, Wen ; Lizheng, Shi ; Herman, William ; McEwan, Phil ; Schramm, Wendelin ; Gray, Alastair ; Leal, Jose ; Lamotte, Mark ; Willis, Michael ; Palmer, Andrew J ; Clarke, Philip. / The Challenge of Transparency and Validation in Health Economic Decision Modelling : A View from Mount Hood. In: Pharmacoeconomics. 2019 ; Vol. 37, No. 11. pp. 1305-1312.

Harvard

Kent, S, Becker, F, Feenstra, T, Tran-Duy, A, Schlackow, I, Tew, M, Zhang, P, Ye, W, Lizheng, S, Herman, W, McEwan, P, Schramm, W, Gray, A, Leal, J, Lamotte, M, Willis, M, Palmer, AJ & Clarke, P 2019, 'The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood', Pharmacoeconomics, vol. 37, no. 11, pp. 1305-1312. https://doi.org/10.1007/s40273-019-00825-1

Standard

The Challenge of Transparency and Validation in Health Economic Decision Modelling : A View from Mount Hood. / Kent, Seamus; Becker, Frauke; Feenstra, Talitha; Tran-Duy, An; Schlackow, Iryna; Tew, Michelle; Zhang, Ping; Ye, Wen; Lizheng, Shi; Herman, William; McEwan, Phil; Schramm, Wendelin; Gray, Alastair; Leal, Jose; Lamotte, Mark; Willis, Michael; Palmer, Andrew J; Clarke, Philip.

In: Pharmacoeconomics, Vol. 37, No. 11, 11.2019, p. 1305-1312.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Kent S, Becker F, Feenstra T, Tran-Duy A, Schlackow I, Tew M et al. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics. 2019 Nov;37(11):1305-1312. https://doi.org/10.1007/s40273-019-00825-1


BibTeX

@article{a082431aacae4a5e9165edcd0de842e8,
title = "The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood",
abstract = "Transparency in health economic decision modelling is important for engendering confidence in the models and in the reliability of model-based cost-effectiveness analyses. The Mount Hood Diabetes Challenge Network has taken a lead in promoting transparency through validation with biennial conferences in which diabetes modelling groups meet to compare simulated outcomes of pre-specified scenarios often based on the results of pivotal clinical trials. Model registration is a potential method for promoting transparency, while also reducing the duplication of effort. An important network initiative is the ongoing construction of a diabetes model registry (https://www.mthooddiabeteschallenge.com). Following the 2012 International Society for Pharmacoeconomics and Outcomes Research and the Society of Medical Decision Making (ISPOR-SMDM) guidelines, we recommend that modelling groups provide technical and non-technical documentation sufficient to enable model reproduction, but not necessarily provide the model code. We also request that modelling groups upload documentation on the methods and outcomes of validation efforts, and run reference case simulations so that model outcomes can be compared. In this paper, we discuss conflicting definitions of transparency in health economic modelling, and describe the ongoing development of a registry of economic models for diabetes through the Mount Hood Diabetes Challenge Network, its objectives and potential further developments, and highlight the challenges in its construction and maintenance. The support of key stakeholders such as decision-making bodies and journals is key to ensuring the success of this and other registries. In the absence of public funding, the development of a network of modellers is of huge value in enhancing transparency, whether through registries or other means.",
keywords = "COMPLICATIONS, REGISTRATION, DISEASE, TIME",
author = "Seamus Kent and Frauke Becker and Talitha Feenstra and An Tran-Duy and Iryna Schlackow and Michelle Tew and Ping Zhang and Wen Ye and Shi Lizheng and William Herman and Phil McEwan and Wendelin Schramm and Alastair Gray and Jose Leal and Mark Lamotte and Michael Willis and Palmer, {Andrew J} and Philip Clarke",
year = "2019",
month = nov,
doi = "10.1007/s40273-019-00825-1",
language = "English",
volume = "37",
pages = "1305--1312",
journal = "Pharmacoeconomics",
issn = "1170-7690",
publisher = "ADIS INT LTD",
number = "11",

}

RIS

TY - JOUR

T1 - The Challenge of Transparency and Validation in Health Economic Decision Modelling

T2 - A View from Mount Hood

AU - Kent, Seamus

AU - Becker, Frauke

AU - Feenstra, Talitha

AU - Tran-Duy, An

AU - Schlackow, Iryna

AU - Tew, Michelle

AU - Zhang, Ping

AU - Ye, Wen

AU - Lizheng, Shi

AU - Herman, William

AU - McEwan, Phil

AU - Schramm, Wendelin

AU - Gray, Alastair

AU - Leal, Jose

AU - Lamotte, Mark

AU - Willis, Michael

AU - Palmer, Andrew J

AU - Clarke, Philip

PY - 2019/11

Y1 - 2019/11

N2 - Transparency in health economic decision modelling is important for engendering confidence in the models and in the reliability of model-based cost-effectiveness analyses. The Mount Hood Diabetes Challenge Network has taken a lead in promoting transparency through validation with biennial conferences in which diabetes modelling groups meet to compare simulated outcomes of pre-specified scenarios often based on the results of pivotal clinical trials. Model registration is a potential method for promoting transparency, while also reducing the duplication of effort. An important network initiative is the ongoing construction of a diabetes model registry (https://www.mthooddiabeteschallenge.com). Following the 2012 International Society for Pharmacoeconomics and Outcomes Research and the Society of Medical Decision Making (ISPOR-SMDM) guidelines, we recommend that modelling groups provide technical and non-technical documentation sufficient to enable model reproduction, but not necessarily provide the model code. We also request that modelling groups upload documentation on the methods and outcomes of validation efforts, and run reference case simulations so that model outcomes can be compared. In this paper, we discuss conflicting definitions of transparency in health economic modelling, and describe the ongoing development of a registry of economic models for diabetes through the Mount Hood Diabetes Challenge Network, its objectives and potential further developments, and highlight the challenges in its construction and maintenance. The support of key stakeholders such as decision-making bodies and journals is key to ensuring the success of this and other registries. In the absence of public funding, the development of a network of modellers is of huge value in enhancing transparency, whether through registries or other means.

AB - Transparency in health economic decision modelling is important for engendering confidence in the models and in the reliability of model-based cost-effectiveness analyses. The Mount Hood Diabetes Challenge Network has taken a lead in promoting transparency through validation with biennial conferences in which diabetes modelling groups meet to compare simulated outcomes of pre-specified scenarios often based on the results of pivotal clinical trials. Model registration is a potential method for promoting transparency, while also reducing the duplication of effort. An important network initiative is the ongoing construction of a diabetes model registry (https://www.mthooddiabeteschallenge.com). Following the 2012 International Society for Pharmacoeconomics and Outcomes Research and the Society of Medical Decision Making (ISPOR-SMDM) guidelines, we recommend that modelling groups provide technical and non-technical documentation sufficient to enable model reproduction, but not necessarily provide the model code. We also request that modelling groups upload documentation on the methods and outcomes of validation efforts, and run reference case simulations so that model outcomes can be compared. In this paper, we discuss conflicting definitions of transparency in health economic modelling, and describe the ongoing development of a registry of economic models for diabetes through the Mount Hood Diabetes Challenge Network, its objectives and potential further developments, and highlight the challenges in its construction and maintenance. The support of key stakeholders such as decision-making bodies and journals is key to ensuring the success of this and other registries. In the absence of public funding, the development of a network of modellers is of huge value in enhancing transparency, whether through registries or other means.

KW - COMPLICATIONS

KW - REGISTRATION

KW - DISEASE

KW - TIME

U2 - 10.1007/s40273-019-00825-1

DO - 10.1007/s40273-019-00825-1

M3 - Article

C2 - 31347104

VL - 37

SP - 1305

EP - 1312

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 11

ER -

ID: 110399402